In clinical studies of advanced NSCLC, from 55% to 75% of patients with high PD-L1 expression did not respond to immunotherapy, whereas 10% of patients with negative PD-L1 expression responded [4,11,14]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.